Senti Biosciences (SNTI) said Monday that the first patient has been dosed in the pilot trial of SN301A to treat hepatocellular carcinoma.
The biotech firm said the trial, which is taking place in mainland China, is part of a collaboration with Celest Therapeutics.
Senti Bio said the two companies have the option to expand clinical development of SN301A to Hong Kong, Macau and Taiwan. It also said it will maintain all development and commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan.
Price: 5.21, Change: -0.36, Percent Change: -6.46
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。